Aspirin therapy for cancer: It is never too late

British Journal of Cancer

Volumn 105, Issue 8, 2011, Pages 1105-1106

  Jankowski, J A Z ^a   Limburg, P J ^b  

^a Old Road Campus ^*  (United Kingdom)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER MORTALITY; CANCER RISK; CANCER THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; COLORECTAL CANCER; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; IMMUNOREGULATION; MALIGNANT NEOPLASTIC DISEASE; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION;

ANTICARCINOGENIC AGENTS; ASPIRIN; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; NEOPLASMS;

EID: 80053977828     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.373     Document Type: Editorial

References (12)

1. Chan AT, Ogino S, Fuchs CS (2009) Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302(6): 649-658
2. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10(5): 501-507
3. Ghosh N, Chaki R, Mandal V, Mandal SC (2010) COX-2 as a target for cancer chemotherapy. Pharmacol Rep 62(2): 233-244
4. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE (2010) Aspirin intake and survival after breast cancer. J Clin Oncol 28(9): 1467-1472
5. Jankowski J, Hawk E (2006) A methodological analysis of chemoprevention in the gastrointestinal tract. Nat Clin Pract Gastro Hep 3: 101-111
6. Jankowski J, Hunt R (2008) Cyclooxygenase-2 inhibitors in colorectal cancer prevention; better the devil you know. Cancer Epidemiol Biomarkers Prevent 17: 1858-1861
7. Kune GA, Kune S, Watson LF (1988) Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48(15): 4399-4404
8. Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MKD, Venning G (2011) Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer 105: 1107-1113
9. Mahdi JG, Mahdi AJ, Mahdi AJ, Bowen ID (2006) The historical analysis of aspirin discovery, its relation to the willow tree and antiproliferative and anticancer potential. Cell Prolif 39(2): 147-155
10. Midgley RS, McConkey CC, Johnstone EC, Dunn JA, Smith JL, Grumett SA, Julier P, Iveson C, Yanagisawa Y, Warren B, Langman MJ, Kerr DJ (2010) Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol 28(30): 4575-4580
11. Moayyedi P, Jankowski JA (2010) Does long term aspirin prevent cancer? BMJ 341: c7326
12. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377(9759): 31-41